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INTRODUCTION
Hazard identification and risk assessment paradigms depend on
the presumption of the similarity of rodents to humans, yet species
specific responses, and the extrapolation of high-dose effects to lowdose exposures can affect the estimation of human risk from rodent
data. As a consequence, a human relevance framework concept was
developed by the International Programme on Chemical Safety
(IPCS) and International Life Sciences Institute (ILSI) Risk
Science Institute (RSI) with the central tenet being the identification of a mode of action (MOA). To perform a MOA analysis, the
key biochemical, cellular, and molecular events need to first be
established, and the temporal and dose-dependent concordance of
each of the key events in the MOA can then be determined. The key
events can be used to bridge species and dose for a given MOA. The
next step in the MOA analysis is the assessment of biological
plausibility for determining the relevance of the specified MOA in
an animal model for human cancer risk based on kinetic and
dynamic parameters. Using the framework approach, a MOA in
animals could not be defined for metal overload. The MOA for
phenobarbital (PB)-like P450 inducers was determined to be unlikely
in humans after kinetic and dynamic factors were considered.
In contrast, after these factors were considered with reference to
estrogen, the conclusion was drawn that estrogen-induced tumors
were plausible in humans. Finally, it was concluded that the
induction of rodent liver tumors by porphyrogenic compounds
followed a cytotoxic MOA, and that liver tumors formed as a result
of sustained cytotoxicity and regenerative proliferation are considered relevant for evaluating human cancer risk if appropriate
metabolism occurs in the animal models and in humans.

Disclaimer: The views expressed in this paper are those of the authors and
do not necessarily reflect the views or policies of the U.S. Environmental
Protection Agency, the Food and Drug Administration National Center for
Toxicological Research, or other institutions represented by the authors.
1
To whom reprint requests should be addressed at ILSI Health and
Environmental Sciences Institute, One Thomas Circle, N.W., 9th Floor,
Washington, DC 20005. E-mail: mholsapple@ilsi.org.

Animal cancer bioassays have been used for more than a half
century to determine whether pesticides, pharmaceuticals,
industrial chemicals, and other products might cause cancer
or other health problems in humans. As such, cancer bioassays
have become the default for testing the carcinogenic potential
of products where human use or exposure is anticipated.
Extrapolations (dose and species) are necessary on animal data
to predict and estimate human cancer risk. Such extrapolations
have been surrounded by intense discussion and debate. Data
from molecular and cellular studies have brought together
a fuller biological understanding of how chemicals induce
neoplasia in animal studies. Such mechanistic work has also
raised doubt about the appropriateness of extrapolating some
positive rodent tumor data to humans. In particular, the use of
rodent liver tumor responses in human cancer risk assessment
has often been controversial and has been extensively debated
within the scientific community.
From 1989 until 1994, the International Life Sciences
Institute (ILSI) Health and Environmental Sciences Institute
(HESI) and the U.S. Environmental Protection Agency (EPA)
co-organized and co-sponsored a series of five Mouse Liver
Tumor Workshops with the ultimate aim being to consider how
mouse liver tumor data should be interpreted with respect to
assessing human cancer risk. At the conclusion of the last
workshop in 1994, the participants considered the following
question as central to the debate, ‘‘What constitutes a definition
of robust evidence for a mode-of-action that would be sufficient
to override a default regulatory posture?’’ (Unpublished
observation; but internal reports available from ILSI HESI
upon request).
The recommendations from these early HESI–EPA workshops provided a foundation upon which to develop a mode of
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action (MOA) framework. The International Programme on
Chemical Safety (IPCS) defined the criteria for accepting
a MOA as adequate for evaluating a specific tumor type in
animals (Sonich-Mullin et al., 2001). Subsequent work conducted by the ILSI Risk Science Institute (RSI) determined
how MOA studies can be used to establish the relevance of
rodent tumors to humans (Cohen et al., 2003; Meek et al.,
2003; Cohen et al., 2004).
Scientists representing academia, government, and industry
organized a workshop at the 2005 Society of Toxicology annual
meeting in New Orleans to determine if this human relevance
framework could be used to analyze five MOAs associated with
rodent liver tumors. This article summarizes the main points
addressed during the Workshop on Mode of Action in
Relevance of Rodent Liver Tumors to Human Cancer Risk.
Following presentations on the pathogenesis of rodent hepatocarcinogenesis, and an overview of the Framework, several
MOAs for rodent liver cancer development were described,
including phenobarbital (PB)-like P450 induction, metal overload, porphyrogenicity, hormone perturbation (i.e., estrogen),
and cytotoxicity. The MOA for peroxisome proliferator activated receptor alpha (PPARa) agonist-induced hepatocarcinogenesis was not included because it had recently been
extensively reviewed, along with an evaluation of its human
relevance (Klaunig et al., 2003).
The pathogenesis of rodent hepatocarcinogenesis: potential applications to human cancer risk. A variety of model
systems of hepatocarcinogenesis in the rat and in the mouse
have been developed that allow the delineation and characterization of the stages of initiation, promotion, and progression as
sequential processes in the pathogenesis of hepatocarcinogenesis (Pitot and Dragan, 2001). Each of these stages has
specific characteristics, including mechanism, dose response,
reversibility, and implications for human risk assessment. This
model has served well for examining theoretical aspects of
carcinogenesis, and its main contribution has been to identify
a distinction between genotoxic (DNA reactive) and nongenotoxic effects of carcinogens.
In the rat, single hepatocytes expressing the placental form of
glutathione-S-transferase (GSTP) have been identified as
putative single initiated cells. Single putatively initiated
hepatocytes expressing specific protooncogenes have been
demonstrated in mice (Satoh et al., 2002). The number of
single GSTP-positive hepatocytes exhibits a linear dose response with DNA-reactive chemical carcinogens, and clonal
growth of about 1% of such hepatocytes results in altered
hepatic foci (AHF), expressing GSTP and other genes in excess
or deficient in normal hepatocytes (Pitot, 1993). The dose
response for the development of AHF to several promoting
agents, including phenobarbital, exhibits a sigmoidal response
with a clear no-effect level and hormetic effect (Tsuda et al.,
2003). Numerous studies argue strongly that promoting agents
selectively (1) enhance cell replication in preneoplastic cells in

AHF and (2) inhibit apoptosis in preneoplastic cells (Kolaja
et al., 1996; Hikita et al., 1997). Studies with such model
systems may have application beyond animals to the human,
especially in relation to the importance of classifying a chemical
as to whether it is an initiating agent, a promoting agent, or
a progressor agent, or whether it is a complete carcinogen
capable of all three of these activities (Dragan et al., 1993).
Framework for evaluating the human relevance of carcinogenic modes of action in animals. Considerable effort has
been expended during the past several decades to evaluate the
MOA for specific chemicals causing cancer in rodents.
However, the key question is the relevance of this MOA to
human risk assessment. A framework was developed by an ILSI
RSI working group sponsored by the U.S. EPA and Health
Canada to address this issue and to provide direction in
determining the relevance of rodent tumors to human health
(Cohen et al., 2003; Meek et al., 2003; Cohen et al., 2004). This
human relevance framework (HRF) describes methods and
decision-tree logic to establish a relationship between early
cellular events and the development of cancer. Knowledge of
key events and the identification of a MOA provide a more
rational basis for human hazard and risk assessment. The HRF
devised by ILSI RSI evolved from the MOA paradigm in
animals established by the IPCS (Sonich-Mullin et al., 2001).
As shown in Figure 1, the process of conducting a MOA
analysis is based on three specific questions:
Is the weight of evidence sufficient to establish the MOA in
animals? This evaluation is performed based on the framework developed by the IPCS/EPA for determining an animal
MOA (Sonich-Mullin et al., 2001). The measurable key
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FIG. 1. Summary of conclusions for various modes of action (MOA) for
rodent liver tumors (RLT) using the human relevance framework (HRF). The
workshop considered the following MOA: metal overload, phenobarbital-like
P450 inducers, cytotoxicity, hormonal toxicity, and porphyrogenicity. The
peroxisome proliferator activated receptor alpha (PPARa) agonists are included
for comparative purposes.

MOA OF RODENT LIVER TUMORS AND HUMAN RISK

events in the MOA are explicitly stated and evaluated. This
is not only useful in formulating a MOA, but it identifies
any data gaps and uncertainties that remain.
Are key events in the animal MOA plausible in humans? This
evaluation is based on a concordance analysis comparing
the information known about the specific key events in both
animals and humans. This evaluation is primarily a qualitative assessment.
Taking into account kinetic and dynamic factors, are key
events in the animal MOA plausible in humans? This is
a more quantitative analysis, which addresses the relevance
of tumorigenicity to a level of exposure, and again relies on
a concordance analysis between the animal model and
humans. This approach focuses not only on dose response
but also on quantitative differences between species in
fundamental biologic processes that can affect exposure.
For the first two questions, data may or may not be available
for the specific chemical in humans, but broad knowledge of
processes involved in humans, including anatomy, physiology,
biochemistry, metabolism, and the like, are critical. Based on
the results of this analysis, a statement of the confidence in the
analysis is made, along with implications for carrying forward
to the remainder of the risk assessment process. This human
relevance framework is focused on hazard identification and
evaluation. If the second and third questions are answered in
the negative, then there is not a cancer hazard for humans and
therefore no cancer risk. Examples based on qualitative differences between species are chemicals producing kidney tumors
in male rats by binding to a2u-globulin. Phenobarbital (PB)induced rat thyroid tumors provide an example where the
qualitative processes (PB induction of thyroid hormone
metabolism, T3 feedback on TSH, and effects on thyroid
proliferation) are the same in rats and humans but where
sufficient quantitative differences exist between species to
indicate that thyroid tumors would not occur in humans no
matter how great the exposure.
Mode of action and human relevance of phenobarbitallike rodent liver carcinogens. Phenobarbital is the prototype
of several rodent hepatocarcinogens (e.g., oxazepam, DDT)
that induce tumors by a non-genotoxic mechanism involving
liver hyperplasia (Williams and Whysner, 1996). In a wide
range of genotoxicity tests, PB is negative and is not cytotoxic
(Whysner et al., 1996; IARC, 2001). A diagnostic effect of PB
is induction of some P450 enzymes, particularly of the CYP2B
family. This effect is due to activation of nuclear receptors,
particularly the constitutive androstane receptor (CAR). However, although there is evidence from studies in knockout mice
that CAR plays an essential role in the carcinogenicity of PB
(Yamamoto et al., 2004), it is uncertain whether CYP induction
is a surrogate for a wider pleiotropic response (Ueda et al.,
2002) or if P450 itself plays a role, e.g., by generation of active
oxygen species (Lehman-McKeeman et al., 1999). Additional
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PB responses that are key in its tumorigenic effect include
increased cell proliferation, inhibition of apoptosis, hypertrophy, and development of altered hepatic foci (Whysner et al.,
1996). These effects are all CAR-dependent (Wei et al., 2000;
Yamamoto et al., 2004). Hence, it is possible to identify a series
of key events for PB-induced liver tumors in rodents that fulfill
criteria proposed by Sonich-Mullin et al. (2001) for a MOA.
Although CAR is expressed, and PB induces CYP enzymes
in human liver, it may act more through the pregnane X receptor
(PXR) than through CAR (Moore et al., 2003). However, there
are exceptions such as phenytoin, which has been shown to
induce CYP2B6 in humans via CAR (Wang et al., 2004). In
addition, there is evidence that human CAR may be activatable
by PB, resulting in the induction of non-P450 genes, including
UGT1A1 (Sugatani et al., 2001). For example, liver size is
increased in humans after prolonged treatment with PB
(Pirttiaho et al., 1982). However, limited studies with human
hepatocytes indicate that such cells are refractory to the
hyperplastic and anti-apoptotic effects of PB (Parzefall et al.,
1991; Hasmall and Roberts, 1999). Moreover, although the data
for concordance analysis for PB are limited, there are convincing data showing that in patients receiving PB for many
years, at doses producing plasma concentrations similar to those
following a carcinogenic dose in rodents, there is no evidence
of a hepatocarcinogenic effect (IARC, 2001; Lamminpaa et al.,
2002). There are a number of data gaps, including the extent to
which this MOA extends to other rodent hepatocarcinogens
that are P450 inducers, the concordance of key events between
rodents and humans, and a more detailed definition of the key
events in rodents (e.g., role of CYP2B, reactive oxygen
species, DNA-methylation). Nevertheless, the situation with
PB affords a somewhat unique opportunity, because extensive
epidemiology data from the clinical applications of this drug
can be used in a human relevance framework to help bridge
some of the data gaps in an inverse direction from the traditional application of the framework. Hence, for those compounds for which there are robust data for a PB-like MOA it
can be concluded that the carcinogenic response is not relevant
to humans.
Mode of action and human relevance of metal overload
and porphyrogenic compounds. Using the recently developed human relevance framework, the MOA for metal overload
(copper and iron) and porphyrinogenic chemical-induced
rodent hepatocellular cancer induction were examined. Iron
and copper overload in the liver are seen in the human diseases
hemochromatosis and Wilson’s disease, respectively (Schilsky
and Oikonomou, 2005). Both iron and copper overload have
been implicated as causal factors in both rodent and human
hepatic cancer (Harrison and Bacon, 2005; Kowdley, 2004,
Powell, 1994). In evaluating a potential MOA for metal
overload in the induction of hepatic neoplasia, multiple
references noting an increase in oxidative damage subsequent
to metal overload were examined (Bartsch and Nair, 2004; Nair
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et al., 1999). Oxidative stress has been implicated as an important factor in the carcinogenesis process in both genotoxic and
nongenotoxic mechanisms (Klaunig and Kamendulis, 2004).
However, using the Framework as depicted in Figure 1, an
expert working group concluded that while copper and/or iron
overload is associated with the development of rodent and
human hepatic neoplasia, evidence that only copper or only
iron overload produces liver cancer in rodents or humans was
not apparent. It was the conclusion of the working group that
additional liver damage, including inflammatory effects, hepatocyte necrosis, cirrhosis, and/or fibrosis were necessary to
produce the liver neoplasia (Greaves et al., 2005). Therefore,
under the restrictions of the Framework definitions, the
working group concluded that without other scientific proof
neither metal produces rodent or human liver cancer.
In the discussion of the metal overload data by the working
group, it became apparent that in iron overload, a frequently
observed pathologic effect was the induction of liver porphyria.
Because of this link to metal overload, this discussion led to
a consideration of the impact of porphyrinogenic compounds
on hepatic rodent neoplasia (Smith et al., 1993). A number of
chemical and pharmaceutical agents produce porphyria and
hepatocellular cancer in rodents. Using the established porphyrinogenic agent, hexachlorobenzene, as a model (Carthew
and Smith, 1994), the expert working group concluded that
porphyrinogenic compounds have a definable MOA for rodent
hepatic cancer that involves a threshold and a chronic, dosedependent, persistent hepatocellular injury with resulting
persistent compensatory hyperplasia, which is discussed below
as a cytotoxic MOA.
Hormonal perturbation as a mode of action for rodent
liver tumors. Because hormonally active agents are believed
to contribute to the development of rodent liver tumors,
perturbation of hormonal regulation should be considered when
determining the MOA of non-genotoxic hepatocarcinogens.
Although the liver is not generally considered a target tissue for
sex hormones, it is quite responsive to these hormones. As an
example, rat liver, but not mouse liver, is responsive to the
carcinogenic actions of estrogen. With respect to humans, the
mode of action observed in rat, namely hormonal perturbation,
is a plausible mechanism for primary liver cancer induction. As
summarized by IARC (1999), two case-control studies of
benign hepatocellular tumors showed a strong relationship
with the duration of use of combined oral contraceptives. Three
cohort studies showed no significant association between the
use of combined oral contraceptives and the incidence of
mortality from liver cancer, but it is important to note that these
studies were characterized by low statistical power. Long-term
use of combined oral contraceptives was associated with an
increase in the risk of hepatocellular carcinoma in all nine casecontrol studies conducted in populations with low incidences of
hepatitis B and C viral infections and chronic liver disease,
which are the major causes of human liver cancer, and in

analyses in which women with these factors were excluded.
Few data are available for the more recent, low-dose contraceptive formulations. In the two case-control studies conducted
in populations with a high prevalence of infection with hepatitis viruses, there was no increase in the risk for hepatocellular carcinoma associated with the use of combined oral
contraceptives; but there was little information on long-term
use. Ultimately, extensive epidemiology has shown a small
increased risk of long-term estrogen-containing contraceptives
with hepatocellular adenomas and less with carcinomas,
although each of these tumors remains rare in the young
female populations exposed. Even though there is a differential
risk for tumor types associated with estrogen treatment, it does
not appear that the adenomas are precursor lesions to the
carcinomas.
The key events in rodent liver carcinogenesis following
exposure to estrogenic agents are perturbation of hormone level
or function, altered cell proliferation to apoptosis balance, and
development of altered foci of cellular alteration. Because this
MOA is receptor-mediated, the use of the framework approach
permits initial development of quantitative risk assessment that
can be applied across species. These types of agents typically
exhibit a threshold, and their effects are dose level-, dose
frequency-, and dose-duration dependent.
Rodent liver tumors: cytotoxicity mode of action. Cytotoxicity is a generally accepted MOA and has been defined for
a number of nongenotoxic rodent carcinogens, including
chloroform-induced liver and kidney tumors and melamineinduced bladder tumors (Andersen et al., 1998; Sonich-Mullin
et al., 2001). A hepatocyte cytotoxicant would produce
continual hepatocyte death, leading to persistent regenerative
growth. Such growth results in more opportunities for ‘‘spontaneous’’ DNA mutations, allowing mutated cells to accumulate and proliferate, and giving rise to preneoplastic foci and,
ultimately, to tumors via further clonal expansion. To define
a cytotoxic MOA in liver, it is critical to ensure that other MOAs
do not contribute significantly to hepatocarcinogenesis. For
instance, it is important to ensure that DNA reactivity is not the
source of the tumor findings. Furthermore, it is important to
establish that there are parallel dose responses (not necessarily
identical) for the key events (i.e., cytotoxicity and proliferation)
and tumors, as well as a specificity of the key events and the
tumor response. Hepatotoxicity can be demonstrated with
histopathology (necrosis and/or apoptosis), with or without
serum enzyme changes. Cell proliferation can be measured by
several methods, such as bromodeoxyuridine (BrdU) labeling
index and/or cell number, and it may need to be evaluated on the
basis of zonal distribution.
Using chloroform as an example, the critical role played
by metabolic activation (e.g., CYP 2E1) in the onset of hepatotoxicity is illustrated. As such, liver tumors formed as
a result of sustained cytotoxicity and regenerative proliferation
are considered relevant for evaluating human cancer risk if
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appropriate metabolism occurs in the animal model and in
humans. A non-linear dose response is expected and will likely
entail a threshold effect.

SUMMARY AND CONCLUSIONS

A survey of chemicals tested in chronic rodent bioassays
showed that the most common target organ is the liver and the
most sensitive species is the mouse (Gold et al., 1991; Gold,
2002). In many cases, the tumor increases were seen only in the
mouse liver and were not observed in other species. Interestingly, the incidence of liver tumors in humans (ageadjusted) in the United States is only 2.4/100,000 (El-Serag and
Mason, 1999), in comparison to much higher frequency tumors
such as prostate, breast, or lung (e.g., 165.4/100,000, 134.1/
100,000, and 62.9/100,000, respectively, as summarized by the
National Cancer Institute in a review from 1973–1999). These
observations can be added to those already discussed above to
provide the basis for understanding why the relevance of rodent
liver tumors to humans has been so intensely discussed and
debated through the years.
In recent years, MOA frameworks were developed through
the ILSI RSI (Meek et al., 2003; Cohen et al., 2004), and the
IPCS (Sonich-Mullin et al., 2001). The RSI MOA framework
was applied to the analysis of the class of PPARa agonists
(Klaunig et al., 2003). A summary of the MOA analysis for
PPARa agonists is depicted in Figure 1. A MOA was identified
(See the first question, above) and determined to be plausible in
humans (second question). However, when kinetic and dynamic factors were considered (third question), the plausibility
of the animal MOA was determined not to be likely in humans.
The primary objective of the present article is to summarize the
discussion that took place during a workshop at the 2005 SOT
meeting, where additional MOAs for rodent liver tumors were
analyzed in terms of the human relevance framework. The
analysis of five MOAs are summarized in Figure 1.
With one exception, animal MOAs were identified and
determined to be feasible in humans. Using the framework
approach, a definable MOA for the formation of hepatic cancer
in rodents by either iron or copper (e.g., metal overload) was not
achievable in animals based on available scientific evidence.
The situation with PB-like P450 inducers afforded a unique
opportunity to capitalize on extensive experience in humans
where no incidence of liver tumors has been observed.
Therefore, this MOA was determined to be unlikely in humans
after considering kinetic and dynamic factors. Once a robust
MOA has been established in rodents, and adequate human data
show no evidence of a carcinogenic response, these data can be
applied to chemicals sharing that MOA. Although a number of
compounds appear to be PB-like from the vantage of the
pleiotropic gene expression changes induced (e.g., specifically
CYP2B induction), it cannot be concluded that this MOA is
similar without further data.

Estrogen and related molecules induce liver tumors in rats.
Although the MOA for hepatocarcinogenicity is not completely understood, it is accepted that estrogen works in a doseand duration-dependent manner, through receptors, to change
cellular function. As such, the hormonal MOA can be
considered a subset of receptor-mediated carcinogenesis.
Several examples of receptor-mediated carcinogenesis have
already been considered, including the MOA for PPARa
agonists and CAR activators. In contrast to these MOA, the
conclusion was that after considering kinetic and dynamic
factors, estrogen-induced modulation should be considered as
plausible in humans. However, because this MOA is receptormediated, agents that induce cancer through this MOA
typically exhibit a threshold, and their effects are dose level-,
dose frequency-, and dose duration-dependent. Also, in
humans, estrogens have not been associated with development
of malignant hepatocellular carcinomas.
Liver tumors formed as a result of sustained cytotoxicity and
regenerative proliferation are considered relevant for evaluating human cancer risk, if appropriate metabolism occurs in the
animal model and in humans. However, because of the dose–
response relationship for cytoxicity and proliferation that is
present with this MOA, a nonlinear model should be used for
human health risk assessment, possibly including a threshold.
Thus, the relevance of the level of human exposure is critical to
the evaluation of potential risk in humans. Using hexachlorobenzene as an example, it was concluded that the induction of
rodent liver cancer by porphyrinogenic compounds followed a
cytotoxic MOA (Carthew and Smith, 1994).
The SOT workshop provided greater insight into the utility
of the MOA-HRF approach as applied to human relevance, and
it identified a number of key data gaps. An understanding of the
MOA of agents underlying liver tumor induction will place the
observation of rodent liver tumors into perspective when
human risk assessment is performed, taking appropriate
account of dose and exposure duration and frequency.
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